Institut Rosell reported a new clinical study showing that Lacidofil, its proprietary probiotic formulation, reduced the symptoms associated with chronic Irritable Bowel Syndrome (IBS). The study, conducted by Dr Z. Bene at the Thomayer’s Teaching Hospital, in Prague, Czech Republic, was published in the international journal Nutrafoods in May 2006.
The study involved 50 patients with at least a 10-year history of chronic IBS. Eighty-eight percent of the patients experienced a reduction of IBS-related complaints, and most of them voluntarily continued to take the probiotic several months after completion of the study. No side effects were reported.
The patients were given three capsules containing the probiotic formula per day to be taken with meals, equivalent to 6 billion colony forming units per day. They also continued with conventional therapy consisting of antispasmodics, sedatives and calcium.
The effects of adding Lacidofil to conventional therapy, taken in conjunction with a good regimen and diet, were assessed though clinical examination by physicians. They measured changes in the frequency of defecation, stool consistency, abdominal pressure and bloating, flatulence and meteorism, abdominal rumbling and sloshing, abdominal pain and abdominal colic.
At the end of the four-month study period, 88 percent of participants had an overall reduction of IBS-related complaints.
Lacidofil is formulated using Lactobacillus Rosell 52 and Lactobacillus Rosell 11, both of which were selected for their action on the intestinal tract.
“Lacidofil was tested in association with conventional treatment over a four-month period, representing a relatively long-lasting trial with a probiotic supplementation in IBS,” said Henri Durand, scientific director of Institut Rosell. “The results were very encouraging as most of the patients reported improvement of their condition. At the end of the trial period fourteen patients refused to quit the supplement because of the improvements, while fifteen of them resumed taking it after a relapse in their condition, and this speaks for itself. Most interestingly, other patients continued to experience alleviation of complaints after withdrawal of the treatment.”
NUTRAfoods, (v5) (1), pp. 20-27 (2006 Jun).